Whistleblower Attorneys Blog
A federal district court judge has denied Pfizer’s motion to dismiss a derivative shareholder suit against the company which alleges that directors and executives at Pfizer are liable for actions that led to a historic $2.3 billion settlement with the U.S. government in 2009. Pfizer entered into this enormous settlement to resolve allegations under the federal False Claims Act and Anti-kickback Statute for alleged “off-label promotion” of various drugs, including Bextra and Celebrex. Continue reading ›